MARKETS / NYSE / Health care / Pharmaceuticals / LLY

NYSE · PHARMACEUTICAL PREPARATIONS · LARGE CAP

ELI Lilly & Co. LLY

19 fiscal years on record · USD · FY2025 reported · SEC filings only

9 YEARS OF DIVIDEND GROWTH

Revenue

$65.2B

▲ 44.7% YoY

Net income

$20.6B

▲ 94.9% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Eli Lilly and Company discovers, develops, manufactures and markets products in a single business segment, human pharmaceutical products. It manufactures and distributes its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. Its products are sold in approximately 90 countries. At the end of 2025, it employed approximately 50,000 people, including approximately 27,000 outside the U.S., with approximately 12,000 engaged in research and development activities. Internal pharmaceutical research focuses primarily on the areas of cardiometabolic health, immunology, neuroscience and oncology. In the U.S., most of its products are distributed through wholesalers, and in 2025, 2024 and 2023 three wholesale distributors, McKesson Corporation, Cencora, Inc. and Cardinal Health, Inc., each accounted for a significant percentage of consolidated revenue. It was incorporated in 1901 in Indiana to succeed to the drug manufacturing business founded in Indianapolis, Indiana, in 1876 by Colonel Eli Lilly.

Written from the business description in ELI LILLY & Co's annual report to the U.S. Securities and Exchange Commission, filed 12 February 2026. Every sentence was checked against that document before publication.

Growth

USD 65.2B

Revenue, FY2025 · full 19-year series below

Revenue $B Net income $B

FY2025 · Revenue 65.2 · Net income 20.6

25.0B50.0B

2007201020132016201920222025

Compound annual growth

Revenue

+31.7%

+21.6%

+12.6%

+7.2%

Net income

+49.0%

+27.2%

+24.0%

+9.8%

EPS, diluted

+49.3%

+27.6%

+26.1%

+11.3%

Dividend / share

+15.2%

Returned to shareholders

+23.5%

+24.4%

+12.7%

+10.4%

3 yrs

5 yrs

10 yrs

15 yrs

Revenue compounded at +21.6% a year over the five years to FY2025 — but profit grew faster: net income at +27.2%, earnings per share at +27.6%.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

32 cents

of every revenue dollar became profit

Operating margin Net margin

FY2025 · Operating 39.5% · Net 31.7%

10%20%30%-5%-10%

200720162025

ROE

FY2025 · ROE 101.2%

50%100%150%-10%-20%-30%

200720162025

Three returns, three denominators.

Return on equity101.2%

Return on assets21.6%

Return on capital employedNot available: we don't have a clean operating profit figure for this period.

Gross margin83.0%

Operating margin39.5%

Net margin31.7%

EBITDAUSD 27.7B

Each USD of equity produced 101 cents of profit this year.

Cash & shareholders

USD 9.5B

returned in FY2025 · dividends + net buybacks

Net buybacks $B Dividends $B

FY2025 · Dividends 5.4 · Net buybacks 4.1

4B8BDividendsNet buybacks

2007201020132016201920222025

Dividends paidUSD 5.4B

Net buybacksUSD 4.1B

Share of profit46.0%

Consecutive raises9 years

USD 5.4B in dividends and USD 4.1B in buybacks — 46% of the year's profit went back to shareholders.

Total assetsUSD 112.5B

EquityUSD 26.5B

CashUSD 7.3B

Gross debtUSD 42.5B

Net debtUSD 35.2B

Current ratio1.58×

Net debt stands at 133% of equity.

The 19-year record

19 fiscal years

Every figure from documents filed with the SEC · USD

row low → row highnegative—not applicable◌not available in our data

LLY, 19-year financial record
Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Revenue $B	65.2	45.0	34.1	28.5	28.3	24.5	22.3	21.5	20.0	21.2	20.0	19.6	23.1	22.6	24.3	23.1	21.8	20.4	18.6
Operating income $B	25.7	12.7	6.6	6.8	6.2	7.2	5.3	3.7	2.3	3.4	2.8	3.0	5.9	4.9	6.1	6.8	◌	◌	◌
EBITDA $B	27.7	14.4	8.1	8.3	7.7	8.6	6.5	5.3	3.9	4.9	4.2	4.4	7.3	6.4	7.5	8.1	◌	◌	◌
Income tax $B	5.1	2.1	1.3	0.6	0.6	1.0	0.6	0.5	2.4	0.6	0.4	0.6	1.2	1.3	1.0	1.5	1.0	0.8	0.9
Net income $B	20.6	10.6	5.2	6.2	5.6	6.2	8.3	3.2	−0.2	2.7	2.4	2.4	4.7	4.1	4.3	5.1	4.3	−2.1	3.0
EPS, diluted $	22.95	11.71	5.80	6.90	6.12	6.79	8.89	3.13	−0.19	2.58	2.26	2.23	4.32	3.66	3.90	4.58	3.94	−1.89	◌
Dividend / sh $	6.23	5.40	4.69	4.07	3.53	3.07	2.68	2.33	2.12	2.05	◌	◌	◌	◌	1.96	1.96	1.96	1.90	◌
Payout %	26	44	78	57	55	43	29	72	−1074	79	88	88	45	53	50	43	50	−99	63
ROE %	101.2	84.6	48.9	63.6	76.4	150.2	133.8	30.2	−1.6	19.2	16.1	14.5	28.9	28.9	33.5	46.2	53.2	−30.8	◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

Compare

This company against its peers

ELI Lilly & Co.vsJohnson & JohnsonSame industry: Pharmaceutical Preparations ELI Lilly & Co.vsMerck & Co. Inc.Same industry: Pharmaceutical Preparations ELI Lilly & Co.vsPfizer Inc.Same industry: Pharmaceutical Preparations ELI Lilly & Co.vsAbbVie Inc.Same industry: Pharmaceutical Preparations ELI Lilly & Co.vsAstraZeneca PLCSame industry: Pharmaceutical Preparations ELI Lilly & Co.vsNovartis AGSame industry: Pharmaceutical Preparations ELI Lilly & Co.vsBristol Myers Squibb Co.Same industry: Pharmaceutical Preparations

Other companies filing in the same sector

MCK · COR · CAH · JNJ · HCA · MRK

Provenance

Company facts, as filed

How we verify · 0 failures in 73 reconciliationsAUDITED

Reconciled in 19 of the 19 fiscal years we could check. Two checks were skipped: the balance sheet is not tagged before 2008. One check was skipped: EPS is not tagged before 2008.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures

ActivityPharmaceutical Preparations

Listed onNYSE

Incorporated inIndiana

Fiscal year endsDecember 31

Data on record since2007